Jay K. Jhaveri, MD, MPH, presents “Industry Perspective: Cxbladder Triage AUA Microhematuria Guidelines Inclusion.”
How to cite: Jhaveri JK. Industry perspective: Cxbladder Triage AUA microhematuria guidelines inclusion. Grand Rounds in Urology. Published February 19, 2025. Accessed Jul 2025. https://grandroundsinurology.com/industry-perspective-cxbladder-triage-aua-microhematuria-guidelines-inclusion/
Industry Perspective: Cxbladder Triage AUA Microhematuria Guidelines Inclusion – Summary
Diane K. Newman, DNP, ANP-BC, FAAN, FAUNA, BCB-PMD, Urology Nurse Practitioner and Adjunct Professor of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, introduces Jay K. Jhaveri, MD, MPH, Senior Medical Director, Pacific Edge Cancer Diagnostics. In this 21-minute presentation, Dr. Jhaveri discusses the key changes in the 2025 AUA microhematuria guidelines and their implications for clinical practice. The updated guidelines emphasize refined risk stratification and a more conservative approach to managing low- and intermediate-risk patients.
Most notably, Dr. Jhaveri shares that the age cutoff for women in the low-risk group has increased from 50 to 60 years, and low-risk has been redefined as “low and negligible risk.” For this group, the new protocol no longer recommends shared decision-making for cystoscopy; a single repeat urinalysis within six months is advised.
The guideline introduces support for using urinary biomarkers for the first time. Among these, the Cxbladder Triage test is the only test to receive a Level A recommendation based on high-quality data from the STRATA trial. Dr. Jhaveri presents real-world data from Kaiser Permanente, where Cxbladder testing was integrated into hematuria workflows. In this large, propensity-matched study, the test significantly reduced cystoscopy and CT urography rates among low-risk patients while maintaining cancer detection accuracy.
Dr. Jhaveri’s presentation underscores how biomarker integration aligns with cost containment and safety in modern urologic care, particularly benefiting patients with chronic microhematuria, including women and men with prior prostate cancer treatment.
